Presentation is loading. Please wait.

Presentation is loading. Please wait.

Demonstration of the cascade of clinical events and metabolic changes that contribute sequentially to progressive clinical deterioration and development.

Published byΠᾰλαιμον Βουρδουμπάς Modified over 5 years ago

Similar presentations

Presentation on theme: "Demonstration of the cascade of clinical events and metabolic changes that contribute sequentially to progressive clinical deterioration and development."— Presentation transcript:

1 Demonstration of the cascade of clinical events and metabolic changes that contribute sequentially to progressive clinical deterioration and development of full-blown episodes of euDKA. Demonstration of the cascade of clinical events and metabolic changes that contribute sequentially to progressive clinical deterioration and development of full-blown episodes of euDKA. BG, blood glucose; CHO, carbohydrate; TGs, triglycerides. Julio Rosenstock, and Ele Ferrannini Dia Care 2015;38: ©2015 by American Diabetes Association

Download ppt "Demonstration of the cascade of clinical events and metabolic changes that contribute sequentially to progressive clinical deterioration and development."

Similar presentations

Prediabetes Burden.

Prediabetes Burden.
Carbohydrate & Lipid Review. 1. Can you name this structure?

Carbohydrate & Lipid Review. 1. Can you name this structure?
Identify barriers to effective patient teaching. Identify and teach to the standards of medical care for the management of Type 2 diabetes Describe the.

Identify barriers to effective patient teaching. Identify and teach to the standards of medical care for the management of Type 2 diabetes Describe the.
Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A.

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A.
Contributions to Type 2 Diabetes. Glucose in balance meal Time in minutes Blood glucose levels, mg/dL -60 0 60 120 180 240 80 Insulin levels, uU/mL Glucagon.

Contributions to Type 2 Diabetes. Glucose in balance meal Time in minutes Blood glucose levels, mg/dL Insulin levels, uU/mL Glucagon.
From: Accuracy of Capillary and Arterial Whole Blood Glucose Measurements Using a Glucose Meter in Patients under General Anesthesia in the Operating Room.

From: Accuracy of Capillary and Arterial Whole Blood Glucose Measurements Using a Glucose Meter in Patients under General Anesthesia in the Operating Room.
From: United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications.

From: United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications.
*** *** *** *** *** *** Supplemental Fig. 1 A B N = 27 N = 15

*** *** *** *** *** *** Supplemental Fig. 1 A B N = 27 N = 15
Tips Need to Consider When Organizing a College Event

Tips Need to Consider When Organizing a College Event
The prevalence of diabetes (A), impaired glucose tolerance (B), impaired fasting glucose (C), and impaired glucose metabolism (D) among those with Finnish.

The prevalence of diabetes (A), impaired glucose tolerance (B), impaired fasting glucose (C), and impaired glucose metabolism (D) among those with Finnish.
ماجستير إدارة المعارض من بريطانيا

ماجستير إدارة المعارض من بريطانيا
A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.
Prediabetes Burden.

Prediabetes Burden.
Metabolic Syndrome (N=160) Non-Metabolic Syndrome (N=138) 107/53

Metabolic Syndrome (N=160) Non-Metabolic Syndrome (N=138) 107/53
Study design. Study design. Each subject with or without type 2 diabetes participated in euglycemic and hypoglycemic clamp visits separated by 4–8 weeks.

Study design. Study design. Each subject with or without type 2 diabetes participated in euglycemic and hypoglycemic clamp visits separated by 4–8 weeks.
The risk of DR progression as related to mean HbA1c during DCCT

The risk of DR progression as related to mean HbA1c during DCCT
Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c.

Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c.
The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.
Time-course changes in blood glucose (BG; A), C peptide (B), and non-esterified fatty acid (NEFA; C) levels. Time-course changes in blood glucose (BG;

Time-course changes in blood glucose (BG; A), C peptide (B), and non-esterified fatty acid (NEFA; C) levels. Time-course changes in blood glucose (BG;
(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Similar presentations

Ads by Google